Candida glabrata: review of epidemiology and antifungal susceptibility

Abstract

Abstract:

Candida glabrata is a pathogenic yeast and the one of the most frequent causative agent of invasive candidiasis.The difficulties arise from its high resistance to azole antifungals.So echinocandins are often used as first-line therapy for C.glabrata invasive infection.However,reports of C.glabrata resistant to both azoles and the echinocandins are of concern.Molecular typing of C.glabrata could provide information on nosocomial transmission and strain variation.Thus,this review intends to present an excerpt of the biology,epidemiology,molecular typing and antifungal susceptibility carried out up to the present.

Key words: Candida glabrata, epidemiology, molecular typing, antifungal susceptibility

CLC Number:

R519.3

HOU Xin, XU Ying-chun, ZHAO Yu-pei. Candida glabrata: review of epidemiology and antifungal susceptibility[J]. Chinese Journal of Mycology, 2016, 11(4): 243-247,242.

References

[1] Wisplinghoff H,Bischoff T,Tallent SM,et al.Nosocomial bloodstream infections in US hospitals:analysis of 24,179 cases from a prospective nationwide surveillance study[J].Clin Infect Dis,2004,39(3):309-317.
[2] Gonzalez GM,Trevino-Rangel RJ,Palma-Nicolas JP,et al.Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico:a nationwide surveillance study[J].J Antimicrob Chemother,2013,68(12):2847-2851.
[3] Pfaller MA,Diekema DJ,Jones RN,et al.International surveillance of bloodstream infections due to Candida species:frequency of occurrence and in vitro susceptibilities to fluconazole,ravuconazole,and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program[J].J Clin Microbiol,2001,39(9):3254-3259.
[4] Xiao M,Fan X,Chen SC,et al.Antifungal susceptibilities of Candida glabrata species complex,Candida krusei,Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China:3 year national surveillance[J].J Antimicrob Chemother,2015,70(3):802-810.
[5] Alexander BD,Johnson MD,Pfeiffer CD,et al.Increasing echinocandin resistance in Candida glabrata:clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations[J].Clin Infect Dis,2013,56(12):1724-1732.
[6] Kaur R,Domergue R,Zupancic M L,et al.A yeast by any other name:Candida glabrata and its interaction with the host[J].Curr Opin Microbiol,2005,8(4):378-384.
[7] Gabaldon T,Martin T,Marcet-Houben M,et al.Comparative genomics of emerging pathogens in the Candida glabrata clade[J].BMC Genomics,2013,14:623.
[8] Pfaller MA,Diekema DJ,Gibbs DL,et al.Results from the ARTEMIS DISK Global Antifungal Surveillance Study,1997 to 2007:a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion[J].J Clin Microbiol,2010,48(4):1366-1377.
[9] Pfaller MA,Castanheira M,Messer SA,et al.Echinocandin and triazole antifungal susceptibility profiles for Candida spp.,Cryptococcus neoformans,and Aspergillus fumigatus:application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program(2009)[J].Diagn Microbiol Infect Dis,2011,69(1):45-50.
[10] Liu W,Tan J,Sun J,et al.Invasive candidiasis in intensive care units in China:in vitro antifungal susceptibility in the China-SCAN study[J].J Antimicrob Chemother,2013,69(1):162-167.
[11] Wang H,Xiao M,Chen SC,et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net(CHIF-NET) Study[J].J Clin Microbiol,2012,50(12):3952-3959.
[12] Redding S W,Dahiya MC,Kirkpatrick WR,et al.Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2004,97(1):47-52.
[13] Luque AG,Biasoli MS,Tosello ME,et al.Oral yeast carriage in HIV-infected and non-infected populations in Rosario,Argentina[J].Mycoses,2009,52(1):53-59.
[14] Chen S C,Tong ZS,Lee OC,et al.Clinician response to Candida organisms in the urine of patients attending hospital[J].Eur J Clin Microbiol,2008,27(3):201-208.
[15] Krcmery V,Barnes AJ.Non-albicans Candida spp.causing fungaemia:pathogenicity and antifungal resistance[J].J Hosp Infect,2002,50(4):243-260.
[16] Cohen Y,Karoubi P,Adrie C,et al.Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients[J].Crit Care Med,2010,38(3):826-830.
[17] Hui M,Ho WH,Lam WH,et al.Candida glabrata fungaemia:the importance of anaerobic blood culture[J].J Med Microbiol,2009,58(Pt 3):396-397.
[18] Shin JH,Chae MJ,Song JW,et al.Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia[J].J Clin Microbiol,2007,45(8):2385-2391.
[19] Scherer S,Stevens DA.Application of DNA typing methods to epidemiology and taxonomy of Candida species[J].J Clin Microbiol,1987,25(4):675-679.
[20] Becker K,Badehorn D,Deiwick S,et al.Molecular genotyping of Candida species with special respect to Candida(Torulopsis) glabrata strains by arbitrarily primed PCR[J].J Med Microbiol,2000,49(6):575-581.
[21] Dodgson AR,Pujol C,Denning DW,et al.Multilocus sequence typing of Candida glabrata reveals geographically enriched clades[J].J Clin Microbiol,2003,41(12):5709-5717.
[22] Lin CY,Chen YC,Lo HJ,et al.Assessment of Candida glabrata strain relatedness by pulsed-field gel electrophoresis and multilocus sequence typing[J].J Clin Microbiol,2007,45(8):2452-2459.
[23] Lockhart SR,Joly S,Pujol C,et al.Development and verification of fingerprinting probes for Candida glabrata[J].Microbiology,1997,143(Pt 12):3733-3746.
[24] Enache-Angoulvant A,Bourget M,Brisse S,et al.Multilocus microsatellite markers for molecular typing of Candida glabrata:application to analysis of genetic relationships between bloodstream and digestive system isolates[J].J Clin Microbiol,2010,48(11):4028-4034.
[25] Castanheira M,Messer SA,Rhomberg PR,et al.Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012:application of new CLSI clinical breakpoints and epidemiological cutoff values[J].Mycopathologia,2014,178(1-2):1-9.
[26] Pappas PG,Kauffman CA,Andes D,et al.Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America[J].Clin Infect Dis,2009,48(5):503-535.
[27] Beyda ND,John J,Kilic A,et al.FKS mutant Candida glabrata:risk factors and outcomes in patients with candidemia[J].Clin Infect Dis,2014,59(6):819-825.
[28] Pfaller MA,Castanheira M,Lockhart SR,et al.Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata[J].J Clin Microbiol,2012,50(4):1199-1203.
[29] Pfaller MA,Andes D,Arendrup MC,et al.Clinical breakpoints for voriconazole and Candida spp.revisited:review of microbiologic,molecular,pharmacodynamic,and clinical data as they pertain to the development of species-specific interpretive criteria[J].Diagn Microbiol and Infec Dis,2011,70(3):330-343.
[30] Pfaller MA,Andes D,Diekema DJ,et al.Wild-type MIC distributions,epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida:Time for harmonization of CLSI and EUCAST broth microdilution methods[J].Drug Resist Updates,2010,13(6):180-195.
[31] Lortholary O,Renaudat C,Sitbon K,et al.Worrisome trends in incidence and mortality of candidemia in intensive care units(Paris area,2002-2010)[J].Intensive Care Med,2014,40(9):1303-1312.
[32] Andes DR,Safdar N,Baddley JW,et al.Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis:a patient-level quantitative review of randomized trials[J].Clin Infect Dis,2012,54(8):1110-1122.
[33] Eschenauer GA,Carver PL,Lin SW,et al.Fluconazole versus an echinocandin for Candida glabrata fungaemia:a retrospective cohort study[J].J Antimicrob Chemother,2013,68(4):922-926.
[34] Ruhnke M,Paiva JA,Meersseman W,et al.Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients[J].Clin Microbiol Infect,2012,18(7):680-687.
[35] Klevay MJ,Horn DL,Neofytos D,et al.Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection[J].Diagn Microbiol Infect Dis,2009,64(2):152-157.
[36] Klevay MJ,Ernst EJ,Hollanbaugh J L,et al.Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection[J].Diagn Microbiol Infect Dis,2008,60(3):273-277.